Clinical Trials Browser

Sarcoma, Ewing

Fallopian Tube Neoplasms, Ovarian Neoplasms

Burkitt Lymphoma, Lymphoma, B-Cell

Breast Neoplasms

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

Advanced Solid Tumors

Ovarian Neoplasms

Breast Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Ovarian Neoplasms

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Unrecognized Condition

Ovarian Neoplasms, Recurrence

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Neoplasm Metastasis

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoid Tumors

Leukemia, Plasma Cell

Multiple Myeloma, Neoplasms, Plasma Cell

Breast Neoplasms

Solid Tumors

Carcinoma, Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

AIDS-related Kaposi sarcoma, Sarcoma, Sarcoma, Kaposi

Solid Tumors

Advanced Cancer

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Clinical Trials

METTSEO

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

LONCA

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors

PEMBOV

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Doxil, Bevacizumab and Temsirolimus Trial

HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

CAELYX

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

Anti-EGFR Immunoliposomes in Solid Tumors

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer

Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers

Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients

Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)